Edition:
United States

Ucb SA (UCB.BR)

UCB.BR on Brussels Stock Exchange

61.49EUR
23 Oct 2017
Change (% chg)

-- (--)
Prev Close
€61.49
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
311,665
52-wk High
€79.05
52-wk Low
€54.84

Chart for

About

Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia,... (more)

Overall

Beta: 0.92
Market Cap(Mil.): €11,958.21
Shares Outstanding(Mil.): 194.51
Dividend: 1.15
Yield (%): 1.31

Financials

  Industry Sector
P/E (TTM): -- 31.71 16.52
EPS (TTM): -- -- --
ROI: -- 14.89 11.32
ROE: -- 16.15 15.18

BRIEF-UCB 9-month revenue up at 3.3 billion euros, 2017 outlook increased

* 9-MONTH REVENUE INCREASED TO € 3.3 BILLION, BY 9%; MAIN PRODUCTS GREW BY 15% TO € 2.6 BILLION

Oct 20 2017

BRIEF-‍Partners Connected Health and UCB announce epilepsy partnership​

* ‍PARTNERS CONNECTED HEALTH AND UCB ANNOUNCE COLLABORATION TO DEVELOP HEALTHCARE SOLUTIONS TO SUPPORT PEOPLE LIVING WITH EPILEPSY​ Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

Oct 11 2017

BRIEF-UCB anti-epileptic drug Vimpat (Lacosamide) receives EU approval for paediatric use

* ANTI-EPILEPTIC DRUG VIMPAT (LACOSAMIDE) RECEIVES EU APPROVAL FOR PAEDIATRIC USE

Sep 21 2017

BRIEF-UCB's Briviact approved by FDA as monotherapy treatment of partial-onset seizures in adults

* NEW INDICATION FOR BRIVIACT (BRIVARACETAM): UCB'S NEWEST ANTIEPILEPTIC DRUG APPROVED BY FDA AS MONOTHERAPY TREATMENT OF PARTIAL-ONSET SEIZURES IN ADULTS Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

Sep 15 2017

BRIEF-UCB and Amgen announce detailed results from the phase 3 ARCH study

* ANNOUNCED ON MONDAY, TOGETHER WITH AMGEN , DETAILED RESULTS FROM THE PHASE 3 ARCH STUDY

Sep 12 2017

BRIEF-UCB H1 net sales up at EUR 2.04 billion; increases FY 2017 outlook

* H1 NET SALES EUR 2.04 BILLION VERSUS EUR 1.85 BILLION YEAR AGO

Jul 27 2017

UCB increases 2017 outlook as profit rises in first half

BRUSSELS, July 27 Belgian pharmaceutical company UCB on Thursday increased its 2017 revenue and profit outlook, after beating analysts' forecasts in the first half of the year.

Jul 27 2017

BRIEF-UCB and Dermira announce US and EU regulatory submissions for Cimzia

* UCB AND DERMIRA ANNOUNCE U.S. AND EU REGULATORY SUBMISSIONS FOR CIMZIA (CERTOLIZUMAB PEGOL) FOR THE TREATMENT OF MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS Source text: http://bit.ly/2ty2bhV Further company coverage: (Gdynia Newsroom)

Jul 25 2017

BRIEF-UCB anti-epileptic drug Vimpat receives EU CHMP positive opinion

* ANTI-EPILEPTIC DRUG VIMPAT RECEIVES EU CHMP POSITIVE OPINION FOR BOTH MONOTHERAPY AND ADJUNCTIVE THERAPY IN CHILDREN AGED 4 YEARS AND OLDER WITH EPILEPSY

Jul 24 2017

BRIEF-UCB's Bimekizumab demonstrates skin clearance in psoriasis study

* READY TO ADVANCE PHASE 3 CLINICAL DEVELOPMENT PROGRAM FOR BIMEKIZUMAB IN PSORIASIS

Jul 21 2017

Earnings vs. Estimates